DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Olaratumab
Olaratumab
Cancer Drug Pharmacology Table
Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
CDER Breakthrough Therapy Designation Approvals Data As of December 31, 2020 Total of 190 Approvals
The Two Tontti Tudiul Lui Hi Ha Unit
Approval Makes Olaratumab the First First-Line Treatment Option for Soft
Your Pharmacy Benefits Welcome to Your Pharmacy Plan
Antibodies for the Treatment of Brain Metastases, a Dream Or a Reality?
PDGF/PDGFR Effects in Osteosarcoma and the “Add-On” Strategy
IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
Injectable Anti-Cancer Medications
Ulipristal Acetate
CDER List of Licensed Biological Products With
(INN) for Biological and Biotechnological Substances
WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
LARTRUVO Safely and Effectively
The Adult Brain Tumor Consortium (ABTC)
2SPD-032 Network Meta-Analysis of Therapeutic Alternatives in Untreated
Supplementary File 1 (PDF, 469 Kib)
Top View
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
September Medical Policy Update 2019
(Olaratumab Injection, 10 Mg/Ml), in • EMD Serono Inc
Specialty Injectables Prior Authorization List
Lartruvo, INN-Olaratumab
Therapeutic Advances in Oncology
“What's New” Medical Pharmaceutical Policy Updates March
Anlotinib: a Novel Multi-Targeting Tyrosine Kinase Inhibitor in Clinical Development
Lilly Data at ASCO Illustrate Patient-Driven Advances in Cancer Care
Candidate Biomarkers for Specific Intraoperative Near-Infrared
Adult Antiemetic Management of Chemotherapy-Induced Nausea
Connecticare Commercial Connecticare Commercial J7192 Advate (Factor VIII)
Oncology Medications Policy (1403)
Medicare Advantage Prior Authorization Requirements List
Emetogenic Potential of Antineoplastic Agents
Clinical Development Program for More Than 50 Years
Lilly Highlights Advancements in Its Oncology Portfolio with New Data at ESMO 2016
Review Report May 17, 2016 Pharmaceuticals and Medical
Oncology Therapy for the Generalist
2019-02-26 ENFORSED FILED Complaint Copy
Developments in the Management of Advanced Soft-Tissue Sarcoma – Olaratumab in Context
Mandatory Specialty Drug List
Olaratumab Exerts Anti-Tumor Activity in Preclinical Models of Pediatric
Table of Contents (PDF)
June 30, 2021 Total Approvals 269 This Report Will Be Updated January and July of Every Year
A Matter of Record (301) 890-4188 2
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Lilly and Merck Expand Immuno-Oncology Collaboration
2SPD-034 Use of Daratumumab Based Treatments in Patients With
Lartruvo, INN-Olaratumab
Study Seeks New AML Therapies Olaratumab
Prior Authorization — Premium
Oncology and Chemo-Support Drug List
Olaratumab: Drug Information
Cancer Drug Costs for a Month of Treatment at Initial Food and Drug Administration Approval
Crizanlizumab-Tmca
(INN) for Biological and Biotechnological Substances
Global Oncology
Precision Cancer Therapy
761038Orig1s000
Paclitaxel-Carboplatin-Pembrolizumab Combination (PC Pembrolizumab) Has Been Recently Authorised in This Indication
Phase I Study of Olaratumab in Japanese Patients with Advanced Solid Tumors
Study Seeks New AML Therapies Olaratumab
Monoclonal Antibodies in Cancer Therapy
Olaratumab (LARTRUVO®) As a New Therapeutic Option in the Treatment of Patients with Advanced Soft Tissue Sarcomas
Assessment of the Evolution of Cancer Treatment Therapies
Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Olaratumab Lartruvo
Notification/Prior Authorization Table-All Products
Olaratumab in Combination with Doxorubicin for Treatment Of
Clinical Development Strategies and Regulatory Outcomes of FDA Approved Biological License Applications – Therapeutic Domain Considerations
Hazardous Medication Precautions: Personal Protective Equipment (Ppe)
Emetogenic Potential of Antineoplastic Agents
Developments in Therapy with Monoclonal Antibodies and Related Proteins
Olaratumab for STS Disappoints in Phase III
Olaratumab (Lartruvo) Reference Number: PA.CP.PHAR.326 Effective Date: 01/18 Coding Implications Last Review Date: 10/30/2019 Revision Log